Evidence map›Paper›PMID 28959968›Full record

ArticleNature2017

Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer.

Zachary D Smith, Jiantao Shi, Hongcang Gu, Julie Donaghey, Kendell Clement, Davide Cacchiarelli, Andreas Gnirke, Franziska Michor, Alexander Meissner

Abstract read
In one paragraph

Article in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. The rebirth of repressive chromatin during early vertebrate development.Annals of the New York Academy of Sciences · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Review

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Zachary D SmithBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Jiantao ShiDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Hongcang GuBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Julie DonagheyBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Kendell ClementBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Davide CacchiarelliBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Andreas GnirkeBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Franziska MichorBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Alexander MeissnerBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

Funding

Regulatory Roles and Dynamics of Nuclear long-noncoding RNAs in PluripotencyP01GM099117 · NIGMS · HARVARD UNIVERSITY · PI MEISSNER, ALEXANDER · 2011 to 2021
$21.2M
Center for Cell CircuitsP50HG006193 · NHGRI · BROAD INSTITUTE, INC. · PI REGEV, AVIV · 2011 to 2015
$15.6M
Center for Cell CircuitsRM1HG006193 · NHGRI · BROAD INSTITUTE, INC. · PI BLAINEY, PAUL CLARK, HACOHEN, NIR · 2016 to 2020
$14.9M
Project 3: Single Cell Measures of Intratumor Diversity for Optimal Breast Cancer TherapyU54CA193461 · NCI · DANA-FARBER CANCER INST · PI MICHOR, FRANZISKA · 2015 to 2020
$11.2M
Epimutations in Offspring Produced by Assisted Reproductive Technologies (ART)R01HD078679 · NICHD · UNIVERSITY OF TEXAS SAN ANTONIO · PI MCCARREY, JOHN R, MEISSNER, ALEXANDER · 2014 to 2018
$3.1M
Generation and characterization of tools for target-specific de novo DNA methylatR01DA036898 · NIDA · HARVARD UNIVERSITY · PI MEISSNER, ALEXANDER · 2013 to 2017
$1.7M
NCI NIH HHS U54 CA193461NHGRI NIH HHS P50 HG006193NHGRI NIH HHS RM1 HG006193NICHD NIH HHS R01 HD078679NIDA NIH HHS R01 DA036898NIGMS NIH HHS P01 GM099117NIH HHS 1P50HG006193
6 · The paper itself

Abstract

In mammals, the canonical somatic DNA methylation landscape is established upon specification of the embryo proper and subsequently disrupted within many cancer types. However, the underlying mechanisms that direct this genome-scale transformation remain elusive, with no clear model for its systematic acquisition or potential developmental utility. Here, we analysed global remethylation from the mouse preimplantation embryo into the early epiblast and extraembryonic ectoderm. We show that these two states acquire highly divergent genomic distributions with substantial disruption of bimodal, CpG density-dependent methylation in the placental progenitor. The extraembryonic epigenome includes specific de novo methylation at hundreds of embryonically protected CpG island promoters, particularly those that are associated with key developmental regulators and are orthologously methylated across most human cancer types. Our data suggest that the evolutionary innovation of extraembryonic tissues may have required co-option of DNA methylation-based suppression as an alternative to regulation by Polycomb-group proteins, which coordinate embryonic germ-layer formation in response to extraembryonic cues. Moreover, we establish that this decision is made deterministically, downstream of promiscuously used-and frequently oncogenic-signalling pathways, via a novel combination of epigenetic cofactors. Methylation of developmental gene promoters during tumorigenesis may therefore reflect the misappropriation of an innate trajectory and the spontaneous reacquisition of a latent, developmentally encoded epigenetic landscape.

Indexed as

DNA MethylationEpigenesis, GeneticGene Expression Regulation, DevelopmentalAnimalsBlastocystCell LineageCpG IslandsEctodermFemaleGene Expression Regulation, NeoplasticGerm LayersHumansMaleMiceNeoplasmsPlacenta

Identifiers

PMID28959968
PMCPMC5789792

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.